Patient-tailored design for selective co-inhibition of leukemic cell subpopulations
Authors:
- Aleksandr IanevskiAIAleksandr Ianevski
- Jenni LahtelaJLJenni Lahtela
- Philipp SergeevPSPhilipp Sergeev
- Bishwa R. GhimireBGBishwa R. Ghimire
- Prson GautamPGPrson Gautam
- Markus Vähä-KoskelaMVMarkus Vähä-Koskela
- Laura TurunenLTLaura Turunen
- Nora LinnavirtaNLNora Linnavirta
- Mika KontroMKMika Kontro
- Kimmo PorkkaKPKimmo Porkka
Open Access
- 19 February 2021
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (8) , eabe4038
Abstract
Machine learning and single-cell data inform personalized drug combinations that selectively co-inhibit cancer cell populations.Keywords
All Related Versions
Funding Information
- Helse Sør-Øst RHF (2020026)
- Novo Nordisk Foundation Center for Basic Metabolic Research (NNF17CC0027852)
- Business Finland
- Research Council of Finland (310507, 313267, 326238, 344698)
- Research Council of Finland (1320185)
- Finnish Medical Foundation
- Sigrid Juselius Foundation
- Cancer Society of Finland
This publication has 68 references indexed in Scilit:
- The microtubule depolymerizing agent CYT997 effectively kills acute myeloid leukemia cells via activation of caspases and inhibition of PI3K/Akt/mTOR pathway proteinsExperimental and Therapeutic Medicine, 2013
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaNew England Journal of Medicine, 2013
- GSVA: gene set variation analysis for microarray and RNA-Seq dataBMC Bioinformatics, 2013
- Interferon-stimulated genes and their antiviral effector functionsCurrent Opinion in Virology, 2011
- Phase II failures: 2008–2010Nature Reviews Drug Discovery, 2011
- Targeting PKC‐mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia‐derived cell lines and blast cellsJournal of Cellular Biochemistry, 2011
- Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34− fractionBlood, 2010
- Genetic Factors Influencing Cytarabine TherapyPharmacogenomics, 2009
- Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumoursAnnals of Oncology, 2009
- Bcl2 phosphorylation and active PKC α are associated with poor survival in AMLLeukemia, 2006